Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trialKentaro Tanaka, Isamu Okamoto, Hajime Asahina et al.|European Journal of Cancer|2021Cited by 50
Design Strategies for Global Clinical Trials of Endovascular Devices for Critical Limb Ischemia (CLI) ― A Joint USA-Japanese Perspective ―Hiroyoshi Yokoi, Michael R. Jaff, Gary M. Ansel et al.|Circulation Journal|2018Cited by 8